Nanobiotix's JNJ-1900, which is in Phase III for HNSCC, exhibited an ORR of 69% in oesophageal cancer, potentially ...

While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary ...

Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...

Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

While overall survival (OS) is the king endpoint in oncology trials, it may be overshadowed by surrogates such as progression-free survival (PFS) and objective response rates (ORR) as outcomes improve ...

The never-ending challenge of finding and recruiting eligible clinical trial participants continues to push sponsors to find new avenues to expedite enrolment. As decentralisation shakes up ...

Recently, artificial intelligence (AI) has been paving the way and helping sponsors with patient identification and participant retention. Digital twins, a new technological frontier in the AI space, ...